Welcome to the UPF Digital Repository

Co-treatment with verapamil and curcumin attenuates the behavioral alterations observed in Williams-Beuren syndrome mice by regulation of MAPK pathway and microglia overexpression

Show simple item record

dc.contributor.author Ortiz Romero, Paula, 1994-
dc.contributor.author González-Simón, Alejandro
dc.contributor.author Egea, Gustavo
dc.contributor.author Pérez Jurado, Luis Alberto
dc.contributor.author Campuzano Uceda, María Victoria
dc.date.accessioned 2021-10-14T06:21:28Z
dc.date.available 2021-10-14T06:21:28Z
dc.date.issued 2021
dc.identifier.citation Ortiz-Romero P, González-Simón A, Egea G, Pérez-Jurado LA, Campuzano V. Co-treatment with verapamil and curcumin attenuates the behavioral alterations observed in Williams-Beuren syndrome mice by regulation of MAPK pathway and microglia overexpression. Front Pharmacol. 2021 Aug 3;12:670785. DOI: 10.3389/fphar.2021.670785
dc.identifier.issn 1663-9812
dc.identifier.uri http://hdl.handle.net/10230/48645
dc.description.abstract Williams-Beuren syndrome (WBS) is a rare neurodevelopmental disorder characterized by a distinctive cognitive phenotype for which there are currently no effective treatments. We investigated the progression of behavioral deficits present in WBS complete deletion (CD) mice, after chronic treatment with curcumin, verapamil, and a combination of both. These compounds have been proven to have beneficial effects over different cognitive aspects of various murine models and, thus, may have neuroprotective effects in WBS. Treatment was administered orally dissolved in drinking water. A set of behavioral tests demonstrated the efficiency of combinatorial treatment. Some histological and molecular analyses were performed to analyze the effects of treatment and its underlying mechanism. CD mice showed an increased density of activated microglia in the motor cortex and CA1 hippocampal region, which was prevented by co-treatment. Behavioral improvement correlated with the molecular recovery of several affected pathways regarding MAPK signaling, in tight relation to the control of synaptic transmission, and inflammation. Therefore, the results show that co-treatment prevented behavioral deficits by recovering altered gene expression in the cortex of CD mice and reducing activated microglia. These findings unravel the mechanisms underlying the beneficial effects of this novel treatment on behavioral deficits observed in CD mice and suggest that the combination of curcumin and verapamil could be a potential candidate to treat the cognitive impairments in WBS patients.
dc.description.sponsorship This work was supported by Ministerio de Ciencia e Innovación (SAF 2017-83039-R to GE and SAF 2016-78508-R (AEI/MINEICO/FEDER, UE) to VC) from the association “Autour des Williams” to VC and Generalitat de Catalunya (2017-SGR1794) to VC.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Frontiers
dc.relation.ispartof Front Pharmacol. 2021 Aug 3;12:670785
dc.rights © 2021 Ortiz-Romero, González-Simón, Egea, Pérez-Jurado and Campuzano. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
dc.rights.uri http://creativecommons.org/licenses/by/4.0/
dc.title Co-treatment with verapamil and curcumin attenuates the behavioral alterations observed in Williams-Beuren syndrome mice by regulation of MAPK pathway and microglia overexpression
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.3389/fphar.2021.670785
dc.subject.keyword Williams–Beuren syndrome
dc.subject.keyword Activated glia
dc.subject.keyword Behavior
dc.subject.keyword Curcumin
dc.subject.keyword Mice
dc.subject.keyword Verapamil
dc.relation.projectID info:eu-repo/grantAgreement/ES/2PE/SAF2017-83039-R
dc.relation.projectID info:eu-repo/grantAgreement/ES/1PE/SAF2016-78508-R
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

In collaboration with Compliant to Partaking